汉森制药(002412) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥250,177,963.58, representing a slight increase of 0.53% compared to ¥248,851,389.62 in the same period last year[4]. - Net profit attributable to shareholders for Q1 2023 was ¥55,067,482.18, reflecting a growth of 6.26% from ¥51,824,070.34 year-on-year[4]. - Total operating revenue for Q1 2023 was CNY 250,177,963.58, a slight increase of 0.53% compared to CNY 248,851,389.62 in Q1 2022[19]. - Net profit for Q1 2023 reached CNY 55,067,482.18, representing a growth of 6.4% from CNY 51,824,070.34 in the same period last year[20]. - The total comprehensive income for Q1 2023 was CNY 60,658,900.25, compared to CNY 49,185,657.62 in Q1 2022, marking a growth of 23.3%[21]. - Earnings per share (EPS) for Q1 2023 was CNY 0.1094, an increase from CNY 0.1030 in Q1 2022[21]. Cash Flow - The net cash flow from operating activities increased by 60.05% to ¥70,447,112.49, up from ¥44,016,378.08 in the previous year[4]. - Cash inflow from operating activities totaled CNY 294,293,986.89, up from CNY 249,825,439.23 in the previous year, indicating a growth of 17.7%[23]. - The net cash flow from financing activities increased by 106.61% to ¥63,703,622.63, compared to the previous year[11]. - The net cash flow from financing activities was ¥2,045,917.55, a recovery from -¥30,970,705.08 in the same quarter last year[24]. - Total cash outflow from operating activities amounted to ¥223,846,874.40, up from ¥205,809,061.15 in Q1 2022[24]. - The net cash flow from investing activities was -¥73,944,830.71, worsening from -¥12,597,750.87 year-over-year[24]. Assets and Liabilities - Total assets at the end of Q1 2023 reached ¥2,368,623,266.25, marking a 3.39% increase from ¥2,290,944,050.05 at the end of the previous year[4]. - The company's total assets as of March 31, 2023, amount to CNY 2,368,623,266.25, an increase from CNY 2,290,944,050.05 at the beginning of the year[17]. - Total current assets are reported at CNY 933,341,824.23, up from CNY 865,402,215.15 at the start of the year[17]. - The total liabilities amount to CNY 413,832,663.08, compared to CNY 396,812,347.13 at the beginning of the year[18]. - The company's cash and cash equivalents at the end of the reporting period are CNY 143,953,813.25, slightly down from CNY 145,405,613.92 at the beginning of the year[16]. - Accounts receivable stand at CNY 238,709,792.19, showing an increase from CNY 232,178,903.25 at the start of the year[16]. - The company has a total of CNY 240,313,858.24 in inventory, down from CNY 246,617,154.53 at the beginning of the year[17]. - The total equity attributable to shareholders grew by 3.20% to ¥1,954,790,603.17 from ¥1,894,131,702.92 at the end of the previous year[4]. - The total equity remains stable at CNY 1,954,790,603.17, unchanged from the previous reporting period[18]. Research and Development - Research and development expenses rose by 41.74% to ¥12,227,616.83, driven by increased investment in the development of new products[9]. - Research and development expenses increased to CNY 12,305,644.26, up 41.5% from CNY 8,682,027.43 in Q1 2022[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,707[13]. - The largest shareholder, Hainan Hansen Holdings (Limited Partnership), holds 42.13% of the shares, totaling 212,006,189 shares[13]. Other Income and Expenses - Other income increased by 142.29% to ¥1,520,860.75, primarily due to government subsidies received[9]. - The company reported a decrease in sales expenses to CNY 101,845,183.83 from CNY 105,570,433.08 in Q1 2022, reflecting a reduction of 3.4%[19]. - Tax payments increased to ¥34,303,087.48 from ¥26,719,717.24 year-over-year[24]. - The company paid ¥49,668,394.58 in employee compensation during the quarter, down from ¥56,186,649.20 in the previous year[24].